Polarean Imaging PLC New system order (5035B)

TIDMPOLX

RNS Number : 5035B

Polarean Imaging PLC

14 February 2022

Polarean Imaging Plc

("Polarean" or the "Company")

New system order

Polarean Imaging plc (AIM: POLX), the medical--imaging technology company, with an investigational drug--device combination product using hyperpolarised xenon-129 gas to enhance magnetic resonance imaging (MRI) in pulmonary medicine, announces the Company has received an additional research unit order for a Xenon Polariser system from McMaster University in Ontario, Canada. The newest unit (version 9820) will supplement the University's existing hyperpolarisation (129) Xe MRI research programme which is currently using a prior Polarean model (version 9800).

The system will be installed in St. Joseph's Healthcare Hamilton ("SJHH"). SJHH is a member of the St. Joseph's Health System ("St. Joseph's") , and is affiliated with McMaster University . St. Joseph's is also home to the Firestone Institute for Respiratory Health, which is an internationally regarded hospital-based centre-of-excellence for adult pulmonary research and patient care.

Richard Hullihen, CEO of Polarean, said: "We are excited that this distinguished Canadian academic and research health centre is extending its utilisation of our (129) Xe MRI technology. This new addition to the University's hyperpolarised (129) Xe MRI research programme will help to support its increasing volume of clinical studies, from both academia and drug industry collaborators. We are pleased to support these researchers' use of our platform as they continue their efforts to advance pulmonary patient care."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

Enquiries:

 
  Polarean Imaging plc                                   www.polarean.com / www.polarean-ir.com 
  Richard Hullihen, Chief Executive                                             Via Walbrook PR 
   Officer 
  Jonathan Allis, Chairman 
 
  Stifel Nicolaus Europe Limited (NOMAD and 
   Sole Corporate Broker)                                                   [phone] 
  Nicholas Moore / Samira Essebiyea / William Palmer-Brown 
   (Healthcare Investment Banking) 
  Nick Adams / Fred Walsh (Corporate 
   Broking) 
 
  Walbrook PR                               Tel: [phone] or [e-mail] 
  Paul McManus / Anna Dunphy                             Mob: [phone] 
                                                                                        741 001 
 
 

About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas ((129) Xe) as an imaging agent to visualise ventilation. (129) Xe gas is currently being studied for visualisation of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.

In October 2020, the Group submitted a New Drug Application ("NDA") to the FDA for hyperpolarised (129) Xe used to evaluate pulmonary function and to visualise the lung using MRI. The Group received a complete response letter on 5 October 2021.

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual economic burden of pulmonary disease in the US is estimated to be over US $150 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCBIGDDDSBDGDB

(END) Dow Jones Newswires

February 14, 2022 01:59 ET (06:59 GMT)